1. Scrip
  2. >>Business
  3. >>Deals

Venture Funding Deals: Gotham Raises $54m To Advance Epitranscriptomics

 
• By Deanna Kamienski, Beth Allan, and Maureen Riordan

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced September and October 2018.

Venture Funding Reg column image

Launched with small molecules licensed from Teva Pharmaceutical Industries Ltd., 89bio concurrently raised $60m through its Series A round. Founding investors OrbiMed Israel and OrbiMed US led the round and were joined by Longitude Capital, RA Capital Management, and Pontifax. (Oct.)

The company’s lead candidate BIO89100 (formerly TEV47948) is a fibroblast growth factor 21 (FGF21) analog in Phase I for nonalcoholic...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business